- The folks at Merck KGaA are studying the effects of Pergoverisr; GONAL-fr; Recombinant human chorionic gonadotrophin (r-hCG) on Infertility in females ages 18 years to 41 years. This clinical trial is slated to start January 2014 and is expected to end circa May 2015.+49 6151 72 5200 Merck KGaA Communication Center
|Recruiting||Merck KGaA Communication Centerfirstname.lastname@example.org||+49 6151 72 5200|
This study is officially titled, "A Phase III, Randomized, Controlled, Single-blind, Multicentre, Parallel Arm Trial to Assess the Efficacy and Safety of Pergoverisr (Follitropin Alfa and Lutropin Alfa) and GONAL-fr (Follitropin Alfa) for Multifollicular Development as Part of an Assisted Reproductive Technology Treatment Cycle in Poor Ovarian Responders, as Defined by the European Society of Human Reproduction and Embryology Criteria."
|Recruiting||Please contact the Merck KGaA Communication Center located in|
Germany - map
|+49 6151 72 5200|
For more study details, please visit this link to ClinicalTrials.gov record, which is the source of this webpage.